NovoCure Eyes Glioblastoma Growth, Cancer Launches and EBITDA Break-Even

NovoCure outlined a strategy to restore growth in its glioblastoma franchise, expand launches for pancreatic and lung cancer indications, and progress toward profitability at the Morgan Stanley Healthcare Conference. The update signals a constructive commercial and financial outlook, though no new financial targets, trial data, or operating metrics were disclosed.